KEY TAKEAWAYS

• EarliPoint Health has received FDA clearance to expand its eye-tracking-based autism assessment system from an initial indication covering children 16 to 30 months to a new upper bound of 95 months, or up to age eight.
• The expansion is driven less by diagnostic ambition than by outcome measurement: the extended age range allows clinicians to reassess children longitudinally as they receive ABA and other intervention services.
• The system is administered by a technician rather than a specialist, with results reviewed and interpreted by a qualified clinician as part of the diagnostic evaluation process, which has allowed some clinical partners to double monthly patient volume and cut evaluation time by 50%, according to the company.
• EarliPoint’s developmental profile tracks three domains, including social disability, language learning potential, and nonverbal learning, and can be aligned with the six-month reauthorization cycle most payers require.
• The platform is currently the only FDA-cleared, eye-tracking-based autism assessment tool on the market, a distinction the company says enhances its credibility with health plans and provider partners.

The median age of autism diagnosis in the United States sits at around 47 months, just under four years old, according to the CDC’s most recent Autism and Developmental Disabilities Monitoring Network data. That number has proven stubborn, resistant to decades of advocacy, expanded screening guidance, and growing public awareness of developmental delays. When concerns surface, families are referred to specialists and told to get in line. In many markets across the country, that line stretches six to twenty-four months, long enough for the most critical window of neuroplasticity to narrow, and sometimes close.

It is into that gap that EarliPoint Health has spent the better part of a decade trying to wedge itself. The company, whose platform uses eye-tracking technology to generate an objective, biomarker-based assessment of a child’s social and developmental profile, received its first FDA clearance in June 2022 for children between 16 and 30 months. The logic was familiar: get to kids earlier, shorten the diagnostic runway, and give families faster access to the intervention services that research suggests are most effective at the youngest ages. Children diagnosed and treated before age three, the data show, are 43% more likely to attend regular education and generate an estimated $1.2 million in lifetime cost-of-care savings, according to research published by Georgia Tech.

Earlier today, EarliPoint announced that the FDA had cleared an expanded age indication, extending the platform’s authorized use through 95 months, or age eight. The company had completed new clinical trials and submitted the package for review; the clearance now allows the system to be used across a substantially larger population of children, including the four out of five who, as EarliPoint notes in its announcement, are diagnosed at later ages.

“We can optimize children’s outcomes for their lifetimes if we diagnose and intervene in toddlerhood,” said Dr. Ami Klin, Scientific Co-Founder of EarliPoint Health, in the company’s announcement. “But 4 of every 5 children with autism are diagnosed at later ages. This expanded clearance allows us to now extend objective and cost-effective diagnosis and assessment to the vast majority of families who have waited, sometimes for years, to gain access to these services.”

Dr. Klin, along with co-founder Dr. Warren Jones, developed the foundational research undergirding the platform over more than two decades, beginning at Yale and continuing at Emory University’s Marcus Autism Center, which is a subsidiary of Children’s Healthcare of Atlanta. The science translates into a clinical tool that tracks a child’s gaze during standardized stimuli, producing a quantitative profile across three developmental domains: social disability, language learning potential, and nonverbal learning. Those outputs serve as proxies to established diagnostic instruments, including the ADOS and the Mullen Scales of Early Learning, but can be generated faster and without requiring a licensed specialist to administer the test.

The Efficiency Case

The first FDA clearance was built around an argument about diagnosis. The second is built, in large part, around an argument about operations.

Because the EarliPoint assessment can be administered by a technician rather than a physician or psychologist, the clinician’s involvement begins only at the point of interpretation, not administration, much as a radiologist reads an MRI scan that a technician has already run. When children test positive, the company reports a low rate of false positives in clinical trial data and in a forthcoming study of use in real-world clinics. This means that specialists receiving the result can move quickly. Early clinical partners have, in the first month of integration, doubled the number of children they see monthly and reduced evaluation time by roughly 50%.

“Families can get in for initial testing much faster, which removes one of the biggest bottlenecks in the diagnostic process,” said Jamie Pagliaro, President and CEO of EarliPoint. “The clinician who receives the result can then move through the diagnostic evaluation significantly more efficiently.”

That efficiency argument resonates in a sector under significant capacity strain. Pediatric and developmental specialists are stretched thin, wait lists at diagnostic centers run long, and the consequences of delay fall hardest on families who are already managing uncertainty about their child’s development. For ABA providers specifically, a faster diagnostic pipeline means faster referrals and faster access to billable services.

From Diagnosis to Outcomes

The more consequential shift introduced by the expanded clearance, at least for the ABA industry’s purposes, may be less about opening a new diagnostic market than about what happens after a child starts receiving services.

ABA providers operate under a reauthorization cycle, typically every six months, in which they are required to demonstrate to payers that the child is making meaningful progress to justify continued hours of service. That process has historically relied on provider-generated data: graphs of skill acquisition, behavior reduction logs, clinician observations. The problem, as Pagliaro frames it, is that this data is inherently subjective and difficult to standardize across a population. Individual children are tracked against their own baselines, not against a normative developmental curve. Payers receive a stack of internal reports and are asked to take them largely on faith.

What EarliPoint is offering, with the extended age range, is a way to bookend that process with objective medical data. A child is assessed at intake. Six months later, after receiving intensive services, they are assessed again. The developmental profile either moved or it did not.

“What we’ve really been missing as a field is those bookends,” Pagliaro said. “Get an objective medical snapshot before intervention, then come back and take that test again afterward. Did everything we did in between actually move the needle?”

The analogy Pagliaro returns to is the pediatric growth chart. A child goes to the doctor, gets weighed and measured, and the result is plotted against a normative curve for their age. Parents see, in an instant, whether their child is developing on track. EarliPoint’s developmental profile aspires to offer something similar for the children receiving ABA: not a stack of internal observations, but a standardized position on a developmental continuum relative to typically developing peers.

That framing speaks directly to a live tension in the ABA industry. The question of dosage, how many hours of therapy a child actually needs, and whether the answer has changed since the field’s foundational research was conducted, has become more contested as payers have grown more skeptical and families have grown more vocal. EarliPoint does not prescribe hours. But it offers, at least in principle, a way to evaluate whether the hours being delivered are generating change.

“The question payers and parents are both asking is: when a clinician recommends that a child spend 25 to 40 hours a week in very intensive one-on-one therapy, is it working?” Pagliaro said. “As a parent, having your child in those environments, away from the activities typical children their age would otherwise be doing, requires real sacrifice. Providers have a responsibility to payers, and to families, to demonstrate whether the interventions they’re recommending are actually generating change.”

Credibility and the Competitive Landscape

For provider partners and payers evaluating the platform, FDA clearance carries weight that most other assessment tools on the market currently cannot match. The initial clearance was supported by studies encompassing more than 1,500 participants across a preceding feasibility trial of roughly 1,089 children and a pivotal multi-site clinical trial of approximately 475; the expanded age indication required a separate trial with 612 additional children. EarliPoint describes itself as the only FDA-cleared, eye-tracking-based autism assessment tool currently available, a distinction that separates it from a small but growing field of competitors using video and artificial intelligence to approach similar diagnostic questions, tools that have not yet achieved the same level of regulatory validation or published scientific rigor.

That regulatory moat is not merely a marketing talking point. A handful of payers have already incorporated EarliPoint into their coverage policies, establishing it as an accepted tool for autism diagnosis, and FDA status is, by Pagliaro’s account, a significant factor in those conversations. A tool cleared through the FDA’s rigorous review process carries a different kind of credibility in a prior authorization meeting than one that is commercially available but uncleared.

“FDA clearance is a very high bar in terms of clinical standards,” Pagliaro said. “It absolutely enhances your credibility with health plans, with providers, and with families.”

For the ABA sector, which has spent years navigating payer skepticism about outcomes and confronting growing scrutiny over authorization practices, the arrival of an objective, biomarker-based measurement tool with FDA clearance represents something the field has not previously had access to at scale: a way to answer the question every stakeholder is asking.

Georgia Medicaid and Centene are among the payers that have publicly incorporated EarliPoint into their coverage policies. Pagliaro notes that the absence of a specific policy does not prevent providers from using the tool. Clinicians can incorporate EarliPoint as part of their diagnostic evaluation and provide supporting documentation as needed to render a diagnosis.